Vir Biotechnology Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN ® dual-masked T-cell engagers iii across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. Footnotes: i Huo, Xingyue et al. "Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients: Development of a Prognostic Nomogram." Studies in health technology and informatics vol. 323 (2025): 164-168. doi:10.3233/SHTI250070 ii 50% premium to the 30 day volume weighted average share price as of February 19, 2026 iii Vir Biotechnology retains exclusive rights to the PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
Current Price
—
Profile
Valuation (TTM)
Market Cap—
P/E—
EV—
P/B—
Shares Out—
P/Sales—
Revenue—
EV/EBITDA—
Vir Biotechnology Inc (VIR) Stock Analysis
Market Cap—
Current Price—
P/E Ratio—
Forward P/E—
PEG Ratio—
EPS—
Book Value—
P/B Ratio—
VIR Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 145M
Revenue
8M
FY19
76M
FY20
1.1B
FY21
1.6B
FY22
86M
FY23
74M
FY24
69M
FY25
Net Income
—
FY19
—
FY20
529M
FY21
516M
FY22
—
FY23
—
FY24
—
FY25
Did you know?
Earnings per share grew at a -2.4% CAGR.
Vir Biotechnology Inc (VIR) Financial Summary
Vir Biotechnology Inc (VIR) is a Healthcare company in the Biotechnology industry, listed on NASDAQ..
..
VIR Key Financial Metrics
| Metric | Value |
|---|
VIR Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $8.09M | $-174.68M |
| FY20 | $76.37M | $-298.67M |
| FY21 | $1.10B | $528.58M |
| FY22 | $1.62B | $515.84M |
| FY23 | $86.18M | $-615.06M |
| FY24 | $74.20M | $-521.96M |
| FY25 | $68.56M | $-437.99M |
About Vir Biotechnology Inc
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN ® dual-masked T-cell engagers iii across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. Footnotes: i Huo, Xingyue et al. "Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients: Development of a Prognostic Nomogram." Studies in health technology and informatics vol. 323 (2025): 164-168. doi:10.3233/SHTI250070 ii 50% premium to the 30 day volume weighted average share price as of February 19, 2026 iii Vir Biotechnology retains exclusive rights to the PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.